Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will today host a Capital Markets Day for analysts, investors and media from 2:15pm to 6:00pm GMT at ME London Hotel, Strand, London WC2R 1HA.
At the meeting, Silence will provide an update on its proprietary and innovative RNAi technology platform and on selected pipeline programmes (Iron Overload Disorders and Alcohol Use Disorder), as well as an overview of the Company’s strategy and operational setup. Speakers from the Company will include:
· Dr Annalisa Jenkins, Board Chair
· Ali Mortazavi, Chief Executive Officer
· Dr Torsten Hoffmann, Chief Operating Officer
· Dr Dmitry Samarsky, Chief Scientific Officer
· Dr Ulrich Zügel, Head of Preclinical Drug Discovery
No material new information will be provided during the presentations.
Following the Company presentations, Silence Therapeutics plc will host a panel discussion on genomics, big data and ways to harness outcomes with genetic medicines such as RNAi. Five key opinion leaders from relevant fields will form the panel.
All presentation materials will be available on the company website at www.silence-therapeutics.com shortly after the event has concluded.